Novartis acquired Mariana Oncology for $1.0B upfront plus up to $750M in milestones (total $1.75B), expanding its radioligand therapy (RLT) pipeline and infrastructure with MC-339 (an actinium-based RLT in small cell lung cancer) plus earlier RLT programs across solid tumors. Announced May 2, 2024, the all-cash acquisition completed in Q2 2024 and is reported as a completed business combination in Novartis's half-year 2024 financials (cash ~$1.1B net of cash acquired, plus contingent milestone consideration). The deal reinforces Novartis's leading radiopharmaceuticals position behind Pluvicto and Lutathera.
Key facts
AnnouncedMay 02, 2024
Deal value$1.8B
Deal typeAcquisition/Merger
Therapeutic areaSmall cell lung cancer (lead), breast/prostate/lung cancer
IndicationsSmall cell lung cancer (lead), breast/prostate/lung cancer
Key assetsMC-339 (actinium-based radioligand therapy) plus RLT pipeline